{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:32:30Z","timestamp":1771669950132,"version":"3.50.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/spc.0b013e3283552d7d","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:23:54Z","timestamp":1371158634000},"page":"348-354","source":"Crossref","is-referenced-by-count":48,"title":["Atypical femoral fractures"],"prefix":"10.1097","volume":"6","author":[{"given":"Eve","family":"Donnelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aasis","family":"Unnanuntana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20211004","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"R2-10-20211004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.","volume":"19","author":"McClung","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R3-10-20211004","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"R4-10-20211004","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"R5-10-20211004","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R6-10-20211004","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy.","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-10-20211004","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use.","volume":"22","author":"Neviaser","year":"2008","journal-title":"J Orthop Trauma"},{"key":"R8-10-20211004","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft.","volume":"364","author":"Schilcher","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-10-20211004","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-009-0962-6","article-title":"Fragility fractures of the hip and femur: incidence and patient characteristics.","volume":"21","author":"Nieves","year":"2010","journal-title":"Osteoporos Int"},{"key":"R11-10-20211004","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jbmr.233","article-title":"Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.","volume":"26","author":"Wang","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R12-10-20211004","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/jbmr.1550","article-title":"Incidence and demography of femur fractures with and without atypical features.","volume":"27","author":"Feldstein","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R13-10-20211004","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2106\/JBJS.J.01199","article-title":"Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.","volume":"93","author":"Puhaindran","year":"2011","journal-title":"J Bone Joint Surg Am"},{"key":"R15-10-20211004","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.bone.2010.12.033","article-title":"Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.","volume":"48","author":"Giusti","year":"2011","journal-title":"Bone"},{"key":"R16-10-20211004","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.","volume":"362","author":"Black","year":"2010","journal-title":"N Engl J Med"},{"key":"R17-10-20211004","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1359\/jbmr.081247","article-title":"Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.","volume":"24","author":"Abrahamsen","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R18-10-20211004","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/jbmr.288","article-title":"Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.","volume":"26","author":"Kim","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R19-10-20211004","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jama.2011.190","article-title":"Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.","volume":"305","author":"Park-Wyllie","year":"2011","journal-title":"JAMA"},{"key":"R20-10-20211004","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00198-011-1804-x","article-title":"Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.","volume":"22","author":"Compston","year":"2011","journal-title":"Osteoporos Int"},{"key":"R21-10-20211004","first-page":"77","article-title":"Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology.","volume":"52","author":"Koh","year":"2011","journal-title":"Singapore Med J"},{"key":"R22-10-20211004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11999-011-1985-9","article-title":"The effect of long-term alendronate treatment on cortical thickness of the proximal femur.","volume":"470","author":"Unnanuntana","year":"2012","journal-title":"Clin Orthop Relat Res"},{"key":"R23-10-20211004","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00198-008-0754-4","article-title":"Changes in nonenzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.","volume":"20","author":"Tang","year":"2009","journal-title":"Osteoporos Int"},{"key":"R24-10-20211004","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bone.2009.11.011","article-title":"Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.","volume":"46","author":"Gourion-Arsiquaud","year":"2010","journal-title":"Bone"},{"key":"R25-10-20211004","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/jbmr.560","article-title":"Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures.","volume":"27","author":"Donnelly","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R26-10-20211004","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bone.2011.09.042","article-title":"Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects.","volume":"49","author":"Tjhia","year":"2011","journal-title":"Bone"},{"key":"R27-10-20211004","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/jor.21574","article-title":"Bone tissue composition varies across anatomic sites in the proximal femur and the iliac crest.","volume":"30","author":"Donnelly","year":"2012","journal-title":"J Orthop Res"},{"key":"R28-10-20211004","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1359\/jbmr.070720","article-title":"Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.","volume":"22","author":"Allen","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R29-10-20211004","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bone.2006.04.028","article-title":"Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.","volume":"39","author":"Allen","year":"2006","journal-title":"Bone"},{"key":"R30-10-20211004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jor.21229","article-title":"Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis.","volume":"29","author":"Brennan","year":"2011","journal-title":"J Orthop Res"},{"key":"R32-10-20211004","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/jor.21464","article-title":"Bisphosphonate treatment delays stress fracture remodeling in the rat ulna.","volume":"29","author":"Kidd","year":"2011","journal-title":"J Orthop Res"},{"key":"R33-10-20211004","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2010.05.015","article-title":"Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair.","volume":"47","author":"Sloan","year":"2010","journal-title":"Bone"},{"key":"R34-10-20211004","first-page":"186","article-title":"The outcome of surgically treated femur fractures associated with long-term bisphosphonate use.","volume":"71","author":"Weil","year":"2011","journal-title":"J Trauma"},{"key":"R35-10-20211004","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R36-10-20211004","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1210\/jc.2010-2520","article-title":"Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.","volume":"96","author":"Gomberg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R38-10-20211004","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1007\/s11999-011-1828-8","article-title":"Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures.","volume":"469","author":"Banffy","year":"2011","journal-title":"Clin Orthop Relat Res"},{"key":"R40-10-20211004","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jama.2011.190","article-title":"Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.","volume":"305","author":"Park-Wyllie","year":"2011","journal-title":"JAMA"}],"container-title":["Current Opinion in Supportive & Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201209000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T06:39:38Z","timestamp":1633502378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201209000-00010"}},"subtitle":["epidemiology, etiology, and patient management"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e3283552d7d","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}